Cytokinetics | CYTK - Operating Profit

Stock Price
75.85
Daily Change
-2.79 -3.55%
Monthly
15.94%
Yearly
144.68%
Q2 Forecast
74.33

Cytokinetics reported $-181.23M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Arca Biopharma USD -34.43M 326K Dec/2025
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
Brainstorm Cell Therapeutics USD -2.24M 197K Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cytokinetics USD -181.23M 2.86M Mar/2026
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Exelixis USD 251.34M 15.43M Mar/2026
Geron USD -236K 10.55M Mar/2026
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026